Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery Disease (ELITE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03208465
Recruitment Status : Completed
First Posted : July 5, 2017
Last Update Posted : August 7, 2019
Sponsor:
Information provided by (Responsible Party):
CHEOL WHAN LEE, M.D., Ph.D, Asan Medical Center

Brief Summary:
This trial evaluates the effects of Empagliflozin versus Sitagliptin, in addition to standard of care, on global myocardial perfusion reserve using dynamic single-photon emission computed tomography (SPECT) images.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus Coronary Disease Drug: Empagliflozin Drug: Sitagliptin Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery disease_ELITE Trial
Actual Study Start Date : August 7, 2017
Actual Primary Completion Date : August 1, 2019
Actual Study Completion Date : August 1, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Patients with Empagliflozin Drug: Empagliflozin
In empagliflozin group, patients will be prescribed empagliflozin 10mg/day.

Active Comparator: Patients with Sitagliptin Drug: Sitagliptin
In sitagliptin group, patients will be prescribed sitagliptin 100mg/day.




Primary Outcome Measures :
  1. Percent change in global myocardial perfusion reserve (MPR) index [ Time Frame: 6 months ]

    Percent change in global myocardial perfusion reserve (MPR) index defined as (global MPR index at 6 months - global MPR index at baseline)/(global MPR index at baseline)x100.

    MPR index=stress myocardial flow/rest myocardial flow



Secondary Outcome Measures :
  1. Percent change in regional MPR index [ Time Frame: 6 months ]
    Percent change in regional MPR index defined as (regional MPR index at 6 months - regional MPR index at baseline)/(regional MPR index at baseline)x100.

  2. Absolute change in regional MPR index [ Time Frame: 6 months ]
  3. Absolute change in global MPR index [ Time Frame: 6 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   19 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men or women at least 19 years of age
  • Type 2 diabetes mellitus
  • Stable coronary artery disease
  • Global myocardial perfusion reserve (MPR) index < 2.5
  • The patient or guardian agrees to the study protocol and the schedule of clinical and dynamic SPECT follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site.

Exclusion Criteria:

  • Contraindications to empagliflozin, Sitagliptin
  • DPP4 inhibitors or Sodium-glucose cotransporter-2(SGLT2) inhibitors within the previous 4 weeks
  • Insulin requiring diabetes
  • Poor glucose control (HbA1C>10 %)
  • Acute coronary syndrome
  • Stent placement within the previous 6 months
  • Previous coronary artery bypass graft surgery within the previous 6 months
  • Planned revascularization within 6 months
  • Heart failure requiring loop diuretics
  • Severe left ventricular hypertrophy (left ventricular septal wall thickness > 13mm)
  • Significant renal disease manifested by creatinine clearance of < 30 ml/min)
  • Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation (alanine transaminase or Aspartate Aminotransferase > 3 times upper limit of normal)
  • Radiopaque material implanted in the chest wall (metal, silicone, etc.)
  • Contraindication to adenosine stress test
  • Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgment of the Investigator, would preclude safe completion of the study.
  • Patient's pregnant or breast-feeding or child-bearing potential
  • Expected life expectancy < 1 year
  • Unwillingness or inability to comply with the procedures described in this protocol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03208465


Locations
Layout table for location information
Korea, Republic of
Asan Medical Center
Seoul, Korea, Republic of
Sponsors and Collaborators
CHEOL WHAN LEE, M.D., Ph.D
Layout table for additonal information
Responsible Party: CHEOL WHAN LEE, M.D., Ph.D, professor, Asan Medical Center
ClinicalTrials.gov Identifier: NCT03208465    
Other Study ID Numbers: AMCCV2016-20
First Posted: July 5, 2017    Key Record Dates
Last Update Posted: August 7, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by CHEOL WHAN LEE, M.D., Ph.D, Asan Medical Center:
Empagliflozin
Sitagliptin
Myocardial perfusion reserve
Additional relevant MeSH terms:
Layout table for MeSH terms
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Sitagliptin Phosphate
Empagliflozin
Hypoglycemic Agents
Physiological Effects of Drugs
Incretins
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Dipeptidyl-Peptidase IV Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Sodium-Glucose Transporter 2 Inhibitors